By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intercept Pharmaceuticals 

450 W 15th Street
Suite 505
New York City  New York  10011  U.S.A.
Phone: 646-747-1000 Fax: 646-747-1001



Company News
Intercept Pharma (ICPT) Reports First Quarter 2017 Financial Results And Provides Business Update 5/4/2017 11:12:31 AM
Intercept Pharma (ICPT) To Report First Quarter 2017 Financial Results On May 4 And Present At Upcoming Conference 4/28/2017 8:02:44 AM
Intercept Pharma (ICPT) Release: NICE Recommends Ocaliva® (Obeticholic Acid) For The Treatment Of Patients With Primary Biliary Cholangitis In England, Wales And Northern Ireland 3/2/2017 9:08:50 AM
Intercept Pharma (ICPT) Reports Full Year 2016 Financial Results And Provides Business Update 2/23/2017 11:14:22 AM
Intercept Pharma (ICPT) To Report 2016 Full Year Financial Results On February 23 And Present At Upcoming Conferences 2/17/2017 8:58:06 AM
Why Investors Are Betting Big Against Gilead (GILD)'s Possible Acquisition Candidate Intercept Pharma (ICPT) 2/17/2017 6:53:18 AM
Why Intercept Pharma (ICPT) Stock Jumped Nearly 10% On Friday After Providing Phase III Update 2/10/2017 8:52:20 AM
Novartis AG (NVS) Rumored to Be Buying Intercept Pharma (ICPT) 12/29/2016 6:43:20 AM
European Commission (EC) Grants Intercept Pharma (ICPT)’s Ocaliva (Obeticholic Acid) Marketing Authorization For The Treatment Of Primary Biliary Cholangiti 12/14/2016 7:13:56 AM
Intercept Pharma (ICPT) Presents New Data At American Association for Study of Liver Diseases Examining The Effects Of Ocaliva (Obeticholic Acid) On Non-Invasive Assessments Of Liver Fibrosis In Patients With PBC 11/11/2016 7:57:30 AM